Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

NCT06144424 is registered in ClinicalTrials.gov with Escient Pharmaceuticals, Inc as lead sponsor.

NCT NCT06144424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06144424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)
Lead sponsor
Escient Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2023
Completion date
July 31, 2024
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis